S McCormack, DT Dunn, M Desai,
DI Dolling,
M Gafos… - The Lancet, 2016 - thelancet.com
Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …